Wells Fargo analyst Mohit Bansal says Friday’s Supreme Court decision to continue the no cost sharing mandate for prevention in the Braidwood case likely removes a key overhang for many generalist investors looking to become constructive on Gilead (GILD) However, “macro headwinds have been keeping them at bay,” the analyst tells investors in a research note. Nevertheless, Wells says the ruling is a win for Gilead and its launch of lenacapavir in pre-exposure prophylaxis. The firm sees potential for a “robust launch, driven by physician excitement and rapid adoption potential.” It keeps an Overweight rating on Gilead with a $140 price target
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- USPSTF ruling a favorable outcome for Gilead, says Morgan Stanley
- Gilead Sciences’ Promising Phase 3 Study on Triple Negative Breast Cancer
- Gilead and Arcus Advance Promising Colorectal Cancer Study
- Gilead and Arcus Advance Phase 2 Study in Lung Cancer Immunotherapy
- Gilead and Arcus Biosciences’ Promising Phase 2 Study Update in Gastrointestinal Cancer